<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="831">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368156</url>
  </required_header>
  <id_info>
    <org_study_id>SAVIOR</org_study_id>
    <nct_id>NCT04368156</nct_id>
  </id_info>
  <brief_title>Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms</brief_title>
  <acronym>SAVIOR</acronym>
  <official_title>A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carlos Tornero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clínico Universitario de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses the efficacy of the Gammacore device reducing the need
      for mechanical ventilation in patients diagnosed of Covid-19
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for mechanical ventilation</measure>
    <time_frame>From randomization to hospital discharge or ICU admission, whatever occurs first, assessed up to two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supplemental oxygen requirements</measure>
    <time_frame>From randomization to hospital discharge or ICU admission, whatever occurs first, assessed up to two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From randomization to hospital discharge or ICU admission, whatever occurs first, assessed up to two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay onset of ventilation</measure>
    <time_frame>From randomization to the day of need for mechanical ventilation or hospital discharge, whatever occurs first, assessed up to two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>From randomization to hospital discharge or ICU admission, whatever occurs first, assessed up to two months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gammacore treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gammaCore® (Vagus nerve stimulation)</intervention_name>
    <description>Vagus nerve stimulation using the gammacore neurostimulation device</description>
    <arm_group_label>Gammacore treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has been tested positive or suspected/presumed positive for CoViD-19

          2. Patients with cough, shortness of breath or respiratory compromise (RR&gt;24/min,
             increased work of breathing.)

          3. O2 Saturation less than or equal to 96% on room air or sensation

          4. Agrees to use the gammaCore®-Sapphire device as intended and to follow all of the
             requirements of the study including recording required study data

          5. Patient is able to provide signed and witnessed Informed Consent

        Exclusion Criteria:

          1. On home/therapy oxygen (i.e. for COPD patients) at baseline prior to development of
             CoViD-19

          2. Is already enrolled in a clinical trial using immunotherapeutic regimen for CoViD-19

          3. Already gammaCore for other medical conditions

          4. A history of aneurysm, intracranial hemorrhage, brain tumors, or significant head
             trauma

          5. Known or suspected severe atherosclerotic cardiovascular disease, severe carotid
             artery disease (eg, bruits or history of transient ischemic attack or cerebrovascular
             accident), congestive heart failure, known severe coronary artery disease, or recent
             myocardial infarction

          6. Uncontrolled high blood pressure (&gt;140/90)

          7. Current implantation of an electrical and/or neurostimulator device, including but not
             limited to a cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain
             stimulator, spinal stimulator, bone growth stimulator, or cochlear implant

          8. Current implantation of metal cervical spine hardware or a metallic implant near the
             gammaCore stimulation site

          9. Belongs to a vulnerable population or has any condition such that his or her ability
             to provide informed consent, comply with the follow-up requirements, or provide
             self-assessments is compromised (e.g. homeless, developmentally disabled and prisoner)

         10. Compromised access to peripheral veinous for blood)

         11. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Tornero, PhD</last_name>
    <phone>610408381</phone>
    <phone_ext>+34</phone_ext>
    <email>carlostornero@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natividad Pozo, PhD</last_name>
    <phone>657375209</phone>
    <phone_ext>+34</phone_ext>
    <email>npozo@incliva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Tornero, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Natividad Pozo, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://cytodyn.com/newsroom/press-releases/detail/391/cytodyn-files-ind-and-protocol-for-phase-2-clinical-trial</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>1 Staats, P., et al. (2018). In E.Krames, et. al (Eds.) Neuromodulation : Comprehensive Textbook of Principles, Technologies, and Therapies Vol 1: Neurostiumulation for Asthma (2nd Edition, pp. 1339-1345). London, United Kingdom: Academic Press, Elsevier.</citation>
  </reference>
  <reference>
    <citation>Miner JR, Lewis LM, Mosnaim GS, Varon J, Theodoro D, Hoffmann TJ. Feasibility of percutaneous vagus nerve stimulation for the treatment of acute asthma exacerbations. Acad Emerg Med. 2012 Apr;19(4):421-9. doi: 10.1111/j.1553-2712.2012.01329.x.</citation>
    <PMID>22506946</PMID>
  </reference>
  <reference>
    <citation>Pavlov VA, Chavan SS, Tracey KJ. Bioelectronic Medicine: From Preclinical Studies on the Inflammatory Reflex to New Approaches in Disease Diagnosis and Treatment. Cold Spring Harb Perspect Med. 2020 Mar 2;10(3). pii: a034140. doi: 10.1101/cshperspect.a034140. Review.</citation>
    <PMID>31138538</PMID>
  </reference>
  <reference>
    <citation>Hoffmann TJ, Mendez S, Staats P, Emala CW, Guo P. Inhibition of histamine-induced bronchoconstriction in Guinea pig and Swine by pulsed electrical vagus nerve stimulation. Neuromodulation. 2009 Oct;12(4):261-9. doi: 10.1111/j.1525-1403.2009.00234.x. Epub 2009 Aug 20.</citation>
    <PMID>22151415</PMID>
  </reference>
  <reference>
    <citation>Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R, Tracey KJ, Tak PP. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8284-9. doi: 10.1073/pnas.1605635113. Epub 2016 Jul 5.</citation>
    <PMID>27382171</PMID>
  </reference>
  <reference>
    <citation>Brock C, Brock B, Aziz Q, Møller HJ, Pfeiffer Jensen M, Drewes AM, Farmer AD. Transcutaneous cervical vagal nerve stimulation modulates cardiac vagal tone and tumor necrosis factor-alpha. Neurogastroenterol Motil. 2017 May;29(5). doi: 10.1111/nmo.12999. Epub 2016 Dec 12.</citation>
    <PMID>27957782</PMID>
  </reference>
  <reference>
    <citation>Tarn J, Legg S, Mitchell S, Simon B, Ng WF. The Effects of Noninvasive Vagus Nerve Stimulation on Fatigue and Immune Responses in Patients With Primary Sjögren's Syndrome. Neuromodulation. 2019 Jul;22(5):580-585. doi: 10.1111/ner.12879. Epub 2018 Oct 17.</citation>
    <PMID>30328647</PMID>
  </reference>
  <reference>
    <citation>Lerman I, Hauger R, Sorkin L, Proudfoot J, Davis B, Huang A, Lam K, Simon B, Baker DG. Noninvasive Transcutaneous Vagus Nerve Stimulation Decreases Whole Blood Culture-Derived Cytokines and Chemokines: A Randomized, Blinded, Healthy Control Pilot Trial. Neuromodulation. 2016 Apr;19(3):283-90. doi: 10.1111/ner.12398. Epub 2016 Mar 15.</citation>
    <PMID>26990318</PMID>
  </reference>
  <reference>
    <citation>Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas-Ballina M, Ashok M, Goldstein RS, Chavan S, Pavlov VA, Metz CN, Yang H, Czura CJ, Wang H, Tracey KJ. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med. 2007 Dec;35(12):2762-8.</citation>
    <PMID>17901837</PMID>
  </reference>
  <reference>
    <citation>Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, Pitkäpaasi M, Blomqvist S, Rönkkö E, Kantele A, Strandin T, Kallio-Kokko H, Mannonen L, Lappalainen M, Broas M, Jiang M, Siira L, Salminen M, Puumalainen T, Sane J, Melin M, Vapalahti O, Savolainen-Kopra C. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020 Mar;25(11). doi: 10.2807/1560-7917.ES.2020.25.11.2000266.</citation>
    <PMID>32209163</PMID>
  </reference>
  <reference>
    <citation>Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 March-April,;34(2):327-331. doi: 10.23812/CONTI-E.</citation>
    <PMID>32171193</PMID>
  </reference>
  <reference>
    <citation>Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019 Feb 21;4(4). pii: 123158. doi: 10.1172/jci.insight.123158. eCollection 2019 Feb 21.</citation>
    <PMID>30830861</PMID>
  </reference>
  <reference>
    <citation>Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome. Front Microbiol. 2019 Jan 29;10:50. doi: 10.3389/fmicb.2019.00050. eCollection 2019.</citation>
    <PMID>30761102</PMID>
  </reference>
  <reference>
    <citation>Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, Whitmore A, Heise MT, Baric RS. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio. 2018 Oct 9;9(5). pii: e01753-18. doi: 10.1128/mBio.01753-18.</citation>
    <PMID>30301856</PMID>
  </reference>
  <reference>
    <citation>McDermott JE, Mitchell HD, Gralinski LE, Eisfeld AJ, Josset L, Bankhead A 3rd, Neumann G, Tilton SC, Schäfer A, Li C, Fan S, McWeeney S, Baric RS, Katze MG, Waters KM. The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus. BMC Syst Biol. 2016 Sep 23;10(1):93.</citation>
    <PMID>27663205</PMID>
  </reference>
  <reference>
    <citation>Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016 Jul;38(4):471-82. doi: 10.1007/s00281-016-0558-0. Epub 2016 Mar 10. Review.</citation>
    <PMID>26965109</PMID>
  </reference>
  <reference>
    <citation>Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, Deming D, Menachery VD, Miller DR, Buus RJ, Bell TA, Churchill GA, Threadgill DW, Katze MG, McMillan L, Valdar W, Heise MT, Pardo-Manuel de Villena F, Baric RS. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet. 2015 Oct 9;11(10):e1005504. doi: 10.1371/journal.pgen.1005504. eCollection 2015 Oct.</citation>
    <PMID>26452100</PMID>
  </reference>
  <reference>
    <citation>Selinger C, Tisoncik-Go J, Menachery VD, Agnihothram S, Law GL, Chang J, Kelly SM, Sova P, Baric RS, Katze MG. Cytokine systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates. BMC Genomics. 2014 Dec 22;15:1161. doi: 10.1186/1471-2164-15-1161.</citation>
    <PMID>25534508</PMID>
  </reference>
  <reference>
    <citation>Burrack KS, Morrison TE. The role of myeloid cell activation and arginine metabolism in the pathogenesis of virus-induced diseases. Front Immunol. 2014 Sep 8;5:428. doi: 10.3389/fimmu.2014.00428. eCollection 2014. Review.</citation>
    <PMID>25250029</PMID>
  </reference>
  <reference>
    <citation>van den Brand JM, Haagmans BL, van Riel D, Osterhaus AD, Kuiken T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol. 2014 Jul;151(1):83-112. doi: 10.1016/j.jcpa.2014.01.004. Epub 2014 Jan 15. Review.</citation>
    <PMID>24581932</PMID>
  </reference>
  <reference>
    <citation>DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardeño JM, Fernandez-Delgado R, Fett C, Castaño-Rodriguez C, Perlman S, Enjuanes L. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014 Jan;88(2):913-24. doi: 10.1128/JVI.02576-13. Epub 2013 Nov 6.</citation>
    <PMID>24198408</PMID>
  </reference>
  <reference>
    <citation>Smits SL, de Lang A, van den Brand JM, Leijten LM, van IJcken WF, Eijkemans MJ, van Amerongen G, Kuiken T, Andeweg AC, Osterhaus AD, Haagmans BL. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010 Feb 5;6(2):e1000756. doi: 10.1371/journal.ppat.1000756.</citation>
    <PMID>20140198</PMID>
  </reference>
  <reference>
    <citation>Kong SL, Chui P, Lim B, Salto-Tellez M. Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. Virus Res. 2009 Nov;145(2):260-9. doi: 10.1016/j.virusres.2009.07.014. Epub 2009 Jul 25.</citation>
    <PMID>19635508</PMID>
  </reference>
  <reference>
    <citation>Wan J, Sun W, Li X, Ying W, Dai J, Kuai X, Wei H, Gao X, Zhu Y, Jiang Y, Qian X, He F. Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics. 2006 May;6(9):2886-94.</citation>
    <PMID>16649161</PMID>
  </reference>
  <reference>
    <citation>Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, Takashima I, Tsutsumi H, Fujii N. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol. 2006 Apr;78(4):417-24.</citation>
    <PMID>16482545</PMID>
  </reference>
  <reference>
    <citation>Yu SY, Hu YW, Liu XY, Xiong W, Zhou ZT, Yuan ZH. Gene expression profiles in peripheral blood mononuclear cells of SARS patients. World J Gastroenterol. 2005 Aug 28;11(32):5037-43.</citation>
    <PMID>16124062</PMID>
  </reference>
  <reference>
    <citation>Yang YH, Huang YH, Chuang YH, Peng CM, Wang LC, Lin YT, Chiang BL. Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Virol. 2005 Sep;77(1):1-7.</citation>
    <PMID>16032747</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Liu CY, Wan YL, Chou CL, Huang KH, Lin HC, Lin SM, Lin TY, Chung KF, Kuo HP. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respir Res. 2005 May 11;6:42.</citation>
    <PMID>15888207</PMID>
  </reference>
  <reference>
    <citation>Steyn E, Mohamed Z, Husselman C. Non-invasive vagus nerve stimulation for the treatment of acute asthma exacerbations-results from an initial case series. Int J Emerg Med. 2013 Mar 19;6(1):7. doi: 10.1186/1865-1380-6-7.</citation>
    <PMID>23510361</PMID>
  </reference>
  <reference>
    <citation>Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32. doi: 10.1128/MMBR.05015-11. Review.</citation>
    <PMID>22390970</PMID>
  </reference>
  <reference>
    <citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3. Erratum in: Intensive Care Med. 2020 Apr 6;:.</citation>
    <PMID>32125452</PMID>
  </reference>
  <reference>
    <citation>Mourdoukoutas AP, Truong DQ, Adair DK, Simon BJ, Bikson M. High-Resolution Multi-Scale Computational Model for Non-Invasive Cervical Vagus Nerve Stimulation. Neuromodulation. 2018 Apr;21(3):261-268. doi: 10.1111/ner.12706. Epub 2017 Oct 27. Review.</citation>
    <PMID>29076212</PMID>
  </reference>
  <reference>
    <citation>Henssen DJHA, Derks B, van Doorn M, Verhoogt N, Van Cappellen van Walsum AM, Staats P, Vissers K. Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon. Cephalalgia. 2019 Aug;39(9):1180-1194. doi: 10.1177/0333102419833076. Epub 2019 Feb 20.</citation>
    <PMID>30786731</PMID>
  </reference>
  <reference>
    <citation>Fornai F, Ruffoli R, Giorgi FS, Paparelli A. The role of locus coeruleus in the antiepileptic activity induced by vagus nerve stimulation. Eur J Neurosci. 2011 Jun;33(12):2169-78. doi: 10.1111/j.1460-9568.2011.07707.x. Epub 2011 May 3. Review.</citation>
    <PMID>21535457</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valencia</investigator_affiliation>
    <investigator_full_name>Carlos Tornero</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

